Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Feb 21, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Newamsterdam Pharma Co N.V.
| 5K |
$19.00 | $95,000.00 | +25.15% | 24.88K |
Feb 13
| |||||||
Newamsterdam Pharma Co N.V.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Newamsterdam Pharma Co N.V.
|
0
|
—
|
—
|
—
|
0
|
Jan 1
| |||||||
Newamsterdam Pharma Co N.V.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Epiphany Technology Acquisition Corp.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Bioplus Acquisition Corp.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Audentes Therapeutics, Inc.
| -315.38K |
$60.00 | -$18,922,500.00 | -100.00% |
0
|
Jan 15
| |||||||
Audentes Therapeutics, Inc.
| -11.00K |
$59.60 | -$655,589.30 | -3.79% | 279.48K |
Dec 23
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -11.00K |
$32.17 | -$353,797.88 | -3.65% | 290.48K |
Sep 23
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -21.00K |
$37.99 | -$793,613.56 | -6.51% | 301.48K |
Jun 24
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -21.56K |
$35.98 | -$776,073.27 | -6.27% | 322.48K |
Mar 25
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 6
| |||||||
Audentes Therapeutics, Inc.
| -32.00K |
$18.65 | -$595,799.00 | -7.84% | 376.38K |
Dec 24
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -24.00K |
$22.49 | -$539,760.00 | -6.43% | 349.35K |
Nov 15
| |||||||
Audentes Therapeutics, Inc.
| -33.00K |
$37.32 | -$1,233,380.50 | -7.04% | 435.93K |
Sep 24
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -33.00K |
$40.75 | -$1,339,497.85 | -6.57% | 468.93K |
Jun 25
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 8
| |||||||
Audentes Therapeutics, Inc.
| -48.00K |
$28.90 | -$1,386,937.28 | -8.73% | 501.93K |
Mar 26
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -18.00K |
$30.88 | -$555,792.20 | -3.75% | 462.59K |
Dec 22
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Oct 8
| |||||||
Audentes Therapeutics, Inc.
| -11.00K |
$28.31 | -$311,903.43 | -2.24% | 480.59K |
Sep 29
| |||||||
Audentes Therapeutics, Inc.
| -18.00K |
$28.34 | -$509,726.59 | -3.53% | 491.59K |
Sep 25
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
| -15.00K |
$19.78 | -$296,682.42 | -3.15% | 460.8K |
Jun 26
|
Scheduled
| ||||||
Audentes Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Aug 24
| |||||||
Audentes Therapeutics, Inc.
| 24.63K |
—
|
—
| +4.45% | 577.7K |
Jul 25
| |||||||
Audentes Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 24
| |||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 7
| |||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Dec 23
| |||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 6
| |||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Dec 23
| |||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Oct 31
| |||||||
Cymabay Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Esperion Therapeutics, Inc.
| 215.52K |
$14.00 |
—
|
∞
| 215.52K |
Jul 1
| |||||||
Esperion Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Maxygen Inc
| 10K |
—
|
—
| +20.00% | 60K |
Jun 6
| |||||||
Maxygen Inc
| 10K |
—
|
—
| +25.00% | 50K |
May 27
| |||||||
Maxygen Inc
| 10K |
—
|
—
| +33.33% | 40K |
May 27
| |||||||
Maxygen Inc
| 30K |
—
|
—
|
∞
| 10K |
Sep 22
| |||||||
Gilead Sciences Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||
Want to view more results?
Unlock the hidden results with your Benzinga Account now. No purchase required.